Document Classification

Section Type: RESULTS

Text: Patients receiving low - or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4 + cell counts (+0. 04 vs +0. 03 vs -0. 02 x 10 (9) / L, respectively ; P <. 001) ; log10 HIV-1 RNA as measured by the Roche assay (-0. 96 vs -0. 77 vs +0. 07 copies/mL, respectively ; P <. 001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0. 59 vs -1. 06 vs -0. 02 copies/mL, respectively ; P <. 011) ; and immune-complex dissociated (ICD) p24 antigen (-74 % vs -68 % vs +27 %, respectively ; P <. 001).